LakeShore Biopharma (LSBCF) AI Stock Analysis

• Market Cap: $32.97M
• Dividend Yield: N/A
• Average Volume (3M): 80.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 758
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 41,212,692
• 10 Day Avg. Volume: 171,434
• 30 Day Avg. Volume: 80,985
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: $0.50 ▼(-37.50% Downside)

LakeShore Biopharma's overall stock score is primarily impacted by its weak financial performance and technical indicators. The company's persistent losses and negative cash flows are significant concerns, compounded by bearish technical signals. The lack of profitability and dividend yield further detracts from its valuation appeal, making it a high-risk investment.

LakeShore Biopharma Business Overview & Revenue Model

Company Description

LakeShore Biopharma (LSB) is a leading biotechnology firm specializing in the research, development, and commercialization of innovative therapeutic solutions in the fields of oncology and autoimmune diseases. The company leverages advanced biopharmaceutical technologies to create novel drug candidates aimed at improving patient outcomes. LSB's portfolio includes a range of biologics and small molecule therapies, with a strong emphasis on precision medicine and personalized treatment regimens.

How the Company Makes Money

LakeShore Biopharma generates revenue primarily through the commercialization of its therapeutic products, which include sales of approved drugs and biologics. The company also engages in strategic partnerships and collaborations with larger pharmaceutical companies for co-development and licensing agreements, which provide significant upfront payments and ongoing royalties based on product sales. Additionally, LSB may receive funding through government grants and research contracts aimed at advancing its clinical trials and product development efforts. The combination of direct product sales, royalties from partnerships, and external funding sources contributes to LSB's overall revenue stream.

LakeShore Biopharma Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

LakeShore Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSBCF, the sentiment is Negative. The current price of 0.8 is above the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.82, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.96 is Neutral, neither overbought nor oversold. The STOCH value of 49.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSBCF.

LakeShore Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	51 Neutral	$96.50M	-32.32	-16.54%	―	202.41%	98.99%
HOWL	48 Neutral	$94.66M	-1.26	-96.08%	―	-100.00%	-22.09%
CASI	46 Neutral	$20.30M	-0.43	-2120.91%	―	41.43%	-50.12%
NRXP	45 Neutral	$70.12M	-1.32	―	―	―	18.51%
LSBCF	38 Underperform	$32.97M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%